Mesa Laboratories, Inc. · NASDAQ:MLAB
Mesa Laboratories — Q2 2027 Earnings Presentation
8 slides from Mesa Laboratories's earnings presentation, Nov 9, 2026
Slide 1: GAAP/Non-GAAP Reconciliations
GAAP/NON-GAAP RECONCILIATIONS Second Quarter Fiscal Year 2027 Earnings Conference Call
Slide 2: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), Mesa Laboratories, Inc. (Mesa) uses certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted EBITDA as a percentage of revenues, t
Slide 3: Definitions of Non-GAAP Financial Measures
Definitions of Non-GAAP Financial Measures • EBITDA is defined as net income (loss) before interest income, interest expense and amortization of debt issuance costs, income tax expense (benefit), and depreciation and amortization of intangible assets expense. • Adjusted EBITDA is defined as EBITDA b
Slide 4: Net Income to Non-GAAP EBITDA and Adjusted EBITDA
GAAP Net Income to Non-GAAP EBITDA and Adjusted EBITDA Unaudited (Amounts in thousands, except percent data) Three Months Ended Three Months Ended Six Months Ended Six Months Ended September 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 Revenues $ 62,336 $ 60,737 $ 122,474 $ 120,
Slide 5: Net Income (Loss) to Non-GAAP Adjusted EBITDA – Trailing Twelve Months
GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA – Trailing Twelve Months Unaudited (Amounts in thousands, except percent data) TTM Ended As % of TTM Ended As % of September 30, 2026 Revenues September 30, 2025 Revenues Revenues $ 251,324 $ 245,255 Net income (loss) (GAAP) $ 6,665 2.7% $ (1,572) (
Slide 6: Operating Income to Non-GAAP Adjusted Operating Income
GAAP Operating Income to Non-GAAP Adjusted Operating Income Unaudited (Amounts in thousands, except per share and percent data) TTM Ended As % of Three Months Ended As % of Three Months Ended As % of September 30, 2026 Revenues September 30, 2026 Revenues September 30, 2025 Revenues Revenues $ 251,3
Slide 7: GAAP to Non-GAAP Organic and Constant Currency Organic Revenues Growth
GAAP to Non-GAAP Organic and Constant Currency Organic Revenues Growth Unaudited Three Months Ended Sterilization and Biopharmaceutical Calibration Solutions Clinical Genomics Total September 30, 2026 Disinfection Control Development Total revenues growth (GAAP) 14.6% (8.2)% 3.5% (8.8)% 2.6% Impact
Slide 8: Gross Profit to Non-GAAP Combined Gross Profit by Business
GAAP Gross Profit to Non-GAAP Combined Gross Profit by Business Unaudited (Amounts in thousands, except percent data) Six Months Ended Sterilization and Calibration Quality Control Biopharmaceutical Clinical Life Sciences Tools Total September 30, 2026 Disinfection Control Solutions Total (non-GAAP)